Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with ...
Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...
Mersana Therapeutics stock opened at $0.48 on Monday. The firm has a market cap of $59.30 million, a price-to-earnings ratio of -0.79 and a beta of 1.39. Mersana Therapeutics has a 1 year low of ...
Revenue: US$40.5m (up 9.9% from FY 2023). Net loss: US$69.2m (loss narrowed by 60% from FY 2023). US$0.56 loss per share (improved from US$1.48 loss in FY 2023). Revenue exceeded analyst estimates ...
Mersana Therapeutics, Inc. (NASDAQ:MRSN) investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues of US$40m beat estimates by a substantial 30 ...
Mersana Therapeutics announced promising Phase ... primarily offset by reduced costs related to clinical development activities for UpRi, a discontinued ADC candidate. General and administrative ...
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) – Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D.
March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics ... with manufacturing and clinical development activities for UpRi, reduced employee compensation expenses following the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results